Nurix Therapeutics 

Nurix Therapeutics 

Yahoo Finance • 21 days ago

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix Therapeutics NRIX continues to make steady progress with bexobrutideg, the company's lead product candidate and primary clinical value driver. Nurix is developing bexobrutideg as an oral, brain-penetrant and highly selective Bruton's... Full story

Yahoo Finance • 22 days ago

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why

Nurix Therapeutics, Inc. (NRIX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impac... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Nurix Therapeutics (NasdaqGM:NRIX) announced a $10 million milestone payment tied to the first in... Full story

Yahoo Finance • 2 months ago

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Nurix Therapeutics, Inc. Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive appr... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nurix Therapeutics, Inc. Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor BRISBANE, Calif., Aug. 04, 2026... Full story

Yahoo Finance • 2 months ago

Nurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 Million Upfront

(RTTNews) - Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, announced the closing of its previously announced global collaboration agreement with Roche Holding AG (RHHBY) to co-develop and co-commercialise Bexo... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Nurix Therapeutics, Inc. BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted prote... Full story

Yahoo Finance • 3 months ago

Nurix Posts Wider Q2 Net Loss As Revenue Drops; Highlights $700 Mln Roche Deal

(RTTNews) - Nurix Therapeutics, Inc. (NRIX) reported financial results for the second quarter ended May 31, 2026, reflecting a wider net loss and a decline in revenue. In addition, the company provided operational and pipeline updates. Co... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes comprehensive clinical... Full story

Yahoo Finance • 3 months ago

Stocks Climb on Strength in Chipmakers

The S&P 500 Index ($SPX) (SPY) today is up +0.47%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.55%.  September E-mini S&P futures (ESU26) are up +0.47%, and September E-mini... Full story

Yahoo Finance • 3 months ago

Stocks Weighed Down by Geopolitical Risks

The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.27%.  September E-mini S&P futures (ESU26) fell -0.35%,... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best biotech stocks on this list. TheFly reported on June 18 that Baird increased its price targe... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?

Nurix Therapeutics, Inc. (NRIX) shares soared 16.4% in the last trading session to close at $22.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.5% gain o... Full story

Yahoo Finance • 3 months ago

Nurix (NRIX) Climbs to 52-Week High — This Deal May Hold the Answer

Nurix Therapeutics Inc. (NASDAQ:NRIX) is one of the 9 Stocks Winning by Double Digits. Nurix Therapeutics extended its gains to an 8th straight session on Thursday, touching a new 52-week high, as investors resumed buying positions follow... Full story

Yahoo Finance • 4 months ago

Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 9, Truist analyst Gregory Renza raised Nurix Therapeutics, Inc. (NASDAQ:NRIX)' price target to $32 from $30. The firm mainta... Full story

Yahoo Finance • 4 months ago

Notable healthcare headlines for the week: GSK, Parabilis Medicines, and Novo Nordisk in focus

Wall Street traded higher on Friday as investors focused on the highly anticipated public debut of SpaceX, with enthusiasm surrounding the offering helping support gains across major U.S. equity indexes. The blue-chip Dow Jones Industrial... Full story

Yahoo Finance • 4 months ago

Roche's $2.3 Billion Nurix Deal Sends Shares Moving

This article first appeared on GuruFocus. Roche Holding AG (RHHBY) has agreed to pay Nurix Therapeutics (NASDAQ:NRIX) as much as $2.3 billion for rights to bexobrutideg, an experimental pill targeting certain blood cancers and potentially... Full story

Yahoo Finance • 4 months ago

Stocks Rally as Buyers Return After AI-Led Selloff

The S&P 500 Index ($SPX) (SPY) today is up +1.01%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.46%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.39%.  June E-mini S&P futures (ESM26) are up +1.00%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 4 months ago

Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying

Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg. Continue Reading... Full story

Yahoo Finance • 4 months ago

Roche and Nurix strike $2.3 billion blood cancer drug deal

Roche entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an investigational oral drug targeting blood cancers, in a deal valued at up to $2.3 billion, th... Full story